The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders
Abstract
RA) and cytogenetically characterized by deletion of the long arm of chromosome 20 (del(20q)), which was detected by fluorescence in situ hybridization (FISH) in 18% and 24.5% of unfractionated marrow and blood mononuclear cells, respectively.Nevertheless, donor cell engraftment was timely and the patient developed mild graft-versus-host disease that promptly responded to therapy.As of July 2005, the patient was alive, clinically well, and in complete remission of her lymphoma.The patient's hematopoietic function after transplantation has been remarkable for thrombocytopenia and mild normocytic anemia without evidence for progression (February 2005: hemoglobin level, 118 g/L [11.8 g/dL]; platelet count, 55 ϫ 10 9 /L; and absolute neutrophil count, 2.04 ϫ 10 9 /L).Current clinical information about the stem cell donor was not available.During the 7 years of posttransplantation follow-up, we analyzed donor cell engraftment in myeloid and lymphoid compartments of both blood and bone marrow using conventional cytogenetics, FISH, and variable number tandem repeats (VNTRs).Chimerism analysis by VNTRs confirmed 100% donor hematopoiesis in lymphoid and myeloid lineages by day 34 after transplantation, which has remained stable to date.Shortly after transplantation, at day 158, approximately 10% of granulocytes and monocytes in the blood carried the del(20q) abnormality; however, this population increased to represent 56% to 73% of blood myeloid cells by 3 and 7 years, respectively, a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, broad inter-individual variability of efficacy exists in normal healthy subjects, patients pre-treated with chemotherapy, and patients with Fanconi anemia[34,35,69,81].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [81]
Citations
Cites
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Carpinelli, M. R., Hilton, D. J., Metcalf, D., Antonchuk, J. L., Hyland, C. D., Mifsud, S. L., Di Rago, L., Hilton, A. A., Willson, T. A., Roberts, A. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401496101 · Cited by 179
Research works printed but not linked: 14
- James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434: 1144-1148. · DOI
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061. · DOI · Paper page
- Kralovics R, Passamonti F, Buser A, et al. A gain-of-function mutation of Jak2 in myeloproliferative disorders. N Engl J Med. 2005;352: 1779-1790. · DOI · Paper page
- Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell. 2005;7: 387-397. · DOI · Paper page
- Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80: 947-958. · DOI
- Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106: 1207-1209. · DOI
- Metcalf D, Carpinelli MR, Hyland C, et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood. 2005;105: 3480-3487. · DOI
- Kasper LH, Boussouar F, Ney PA, et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature. 2002;419: 738-743. · DOI
- Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65: 677-689. · DOI
- Frampton J, McNagny K, Sieweke M, Philip A, Smith G, Graf T. v-Myb DNA binding is required to block thrombocytic differentiation of Myb-Ets-transformed multipotent haematopoietic progenitors. EMBO J. 1995;14: 2866-2875. · DOI
- Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88: 402-409. · DOI
- Vannucchi AM, Bianchi L, Paoletti F, Di Giacomo V, Migliaccio G, Migliaccio AR. Impaired GATA-1 expression and myelofibrosis in an animal model. Pathol Biol (Paris). 2004;52: 275-279. · DOI
- Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002; 100: 1123-1132. · DOI
- Slamon DJ, Boone TC, Murdock DC, et al. Studies of the human c-myb gene and its product in human acute leukemias. Science. 1986;233: 347-351. · DOI
Cited by
Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia
Müller, L. U. W., & Williams, D. A. (2009) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2009.03.010 · Cited by 31
Metadata
- Authors
- Steensma, D. P., & Pardanani, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-02-15
- Volume
- 107
- Issue
- 4
- Pages
- 1733-1735
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 10
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
